MEK interactions tune RAF kinase sensitivity to conformation-selective inhibition

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• RAF kinases are central to the RAS-RAF-MEK-ERK pathway, a key target in cancer therapy.
• DFG-out-stabilizing RAF inhibitors show variable efficacy in KRAS-mutant cancers.

Purpose of the Study:

• To investigate the determinants of DFG-out-stabilizing RAF inhibitor potency in KRAS-mutant cell lines.
• To explore strategies for enhancing the efficacy of RAF inhibitors through combination therapy.

Main Methods:

• Cellular assays to assess RAF kinase activity and inhibitor sensitivity.
• Biochemical assays to analyze RAF-MEK interactions and dimer formation.
• Development and testing of cobimetinib analogs.

Main Results:

• Inhibitor potency directly correlates with basal RAF activity.
• DFG-out-stabilizing inhibitors promote inhibited RAF dimer formation by disrupting high-affinity RAF-MEK interactions.
• Cobimetinib sensitizes RAF kinases to DFG-out-stabilizing inhibitors by disrupting autoinhibited RAF-MEK complexes.

Conclusions:

• Basal RAF activity is a key cellular determinant of DFG-out-stabilizing RAF inhibitor sensitivity.
• Disruption of RAF-MEK complexes is crucial for inhibitor efficacy.
• Optimized cobimetinib analogs enhance synergistic RAF-MEK inhibition, offering improved cancer therapeutic strategies.